Skip to content

Novavax NVAX Impairment charges for facilities consolidation

Impairment charges for facilities consolidation at other companies

Valero Energy logo
Valero EnergyVLO
$0-100%
Meta Platforms, Inc. logo
Meta Platforms, Inc.META
$0-100%
Monster Beverage logo
Monster BeverageMNST
$0-100%
Ingredion logo
IngredionINGR
$2.5M-90.8%
LXP Industrial Trust logo
LXP Industrial TrustLXP
$0
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$12.18M

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's impairment charges for facilities consolidation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's impairment charges for facilities consolidation?
Novavax (NVAX) reported impairment charges for facilities consolidation of $266K in Q1 2026.